Replies to post #1111 on Bristol Myers Squibb (BMY)

[DewDiligence]

BMY 3Q22 CC slides:

https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-2022-Q3-Results-Investor-Presentation.pdf

[DewDiligence]

BMY 4Q22 results—2023 guidance:

https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2022/default.aspx

2023 non-GAAP EPS guidance is $7.95-8.25; at the midpoint of the range, this is a 4% increase relative to 2022’s non-GAAP EPS of $7.70.